KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Intangibles: 2009-2024

Historic Intangibles for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Dec 2024 value amounting to $255.3 million.

  • Biomarin Pharmaceutical's Intangibles fell 10.66% to $233.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $233.1 million, marking a year-over-year decrease of 10.66%. This contributed to the annual value of $255.3 million for FY2024, which is 13.38% down from last year.
  • Latest data reveals that Biomarin Pharmaceutical reported Intangibles of $255.3 million as of FY2024, which was down 13.38% from $294.7 million recorded in FY2023.
  • Biomarin Pharmaceutical's 5-year Intangibles high stood at $417.3 million for FY2020, and its period low was $255.3 million during FY2024.
  • In the last 3 years, Biomarin Pharmaceutical's Intangibles had a median value of $294.7 million in 2023 and averaged $296.2 million.
  • Data for Biomarin Pharmaceutical's Intangibles shows a maximum YoY dropped of 13.38% (in 2024) over the last 5 years.
  • Over the past 5 years, Biomarin Pharmaceutical's Intangibles (Yearly) stood at $417.3 million in 2020, then decreased by 6.86% to $388.7 million in 2021, then declined by 12.89% to $338.6 million in 2022, then decreased by 12.96% to $294.7 million in 2023, then dropped by 13.38% to $255.3 million in 2024.